Press release
Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regene
"Exosomes Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Exosomes Market.
The Exosomes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Exosomes Pipeline Report: https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Exosomes treatment therapies with a considerable amount of success over the years.
• Exosomes companies working in the treatment market are Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Aegle Therapeutics, Regeneus, Direct Biologics, Capricor Therapeutics, and others, are developing therapies for the Exosomes treatment
• Emerging Exosomes therapies in the different phases of clinical trials are- ExoCoVac, COYA 201, EV-101, StemXO, BRE AD01, ILB 202, Zofin, exoSTING, AGLE 102, Progenza, ExoFl, CAP-1002, and others are expected to have a significant impact on the Exosomes market in the coming years.
• In January 2025, RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, has successfully completed patient enrollment in its Phase 2 clinical trial for Purified Exosome ProductTM (PEPTM), aimed at treating Diabetic Foot Ulcers (DFUs). This milestone marks a significant step forward in the company's mission to create groundbreaking therapies for chronic wound care.
• In January 2025, NurExone Biologic announced the acquisition of a master cell bank from a U.S. manufacturer. This acquisition is a key milestone in ensuring a stable and scalable supply chain for the production of exosome-based therapies, meeting clinical needs and laying the foundation for future patient treatments.
• In July 2024, Aruna Bio announced that it has been granted a US patent for the composition of neural exosomes intended to deliver therapeutics directly to the brain.
Exosomes Overview
Exosomes are small membrane-bound vesicles that are released by cells into the extracellular space. These vesicles play a crucial role in intercellular communication by transporting various biomolecules, including proteins, lipids, and nucleic acids, between cells. Exosomes are a type of extracellular vesicle, and they are part of the body's natural communication system.
Get a Free Sample PDF Report to know more about Exosomes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Exosomes Drugs Under Different Phases of Clinical Development Include:
• ExoCoVac: Innovex Therapeutics
• COYA 201: Coya Therapeutics
• EV-101: EV Therapeutics
• StemXO: Endosome Therapy StemXO Therapeutics
• BRE AD01: Brexogen
• ILB 202: ILIAS Biologics
• Zofin: Organicell Regenerative Medicine
• exoSTING: Codiak BioSciences
• AGLE 102: Aegle Therapeutics
• Progenza: Regeneus
• ExoFlo: Direct Biologics
• CAP-1002: Capricor Therapeutics
Exosomes Route of Administration
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Exosomes Molecule Type
Exosomes Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Exosomes Pipeline Therapeutics Assessment
• Exosomes Assessment by Product Type
• Exosomes By Stage and Product Type
• Exosomes Assessment by Route of Administration
• Exosomes By Stage and Route of Administration
• Exosomes Assessment by Molecule Type
• Exosomes by Stage and Molecule Type
DelveInsight's Exosomes Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Exosomes product details are provided in the report. Download the Exosomes pipeline report to learn more about the emerging Exosomes therapies
https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Exosomes Therapeutics Market include:
Key companies developing therapies for Exosomes are - Qiagen, Thermo Fisher Scientific Inc., Illumina Inc., Takara Bio Inc., Malvern Instruments Ltd, Abcam PLC, Evox Therapeutics, Danaher Corporation (Beckman Coulter Inc.), Hologic Inc., Fujifilm Holdings Corporation, Lonza Group Ltd, JSR Corporation (MBL International), Miltenyi Biotec, Bio-Techne (Novus Biologicals), Capricor Therapeutics Inc., and others.
Exosomes Pipeline Analysis:
The Exosomes pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
• Exosomes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Exosomes drugs and therapies
https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Exosomes Pipeline Market Drivers
• Exosomes as an emerging messenger in diagnostics, a rise in exosome-based drug development, exosomes as a promising tool in the field of nanomedicine are some of the important factors that are fueling the Exosomes Market.
Exosomes Pipeline Market Barriers
• However, lack of standardized techniques for the isolation and purification of exosomes, lack of scalable manufacturing processes and other factors are creating obstacles in the Exosomes Market growth.
Scope of Exosomes Pipeline Drug Insight
• Coverage: Global
• Key Exosomes Companies: Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Aegle Therapeutics, Regeneus, Direct Biologics, Capricor Therapeutics, and others
• Key Exosomes Therapies: ExoCoVac, COYA 201, EV-101, StemXO, BRE AD01, ILB 202, Zofin, exoSTING, AGLE 102, Progenza, ExoFl, CAP-1002, and others
• Exosomes Therapeutic Assessment: Exosomes current marketed and Exosomes emerging therapies
• Exosomes Market Dynamics: Exosomes market drivers and Exosomes market barriers
Request for Sample PDF Report for Exosomes Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Exosomes Report Introduction
2. Exosomes Executive Summary
3. Exosomes Overview
4. Exosomes- Analytical Perspective In-depth Commercial Assessment
5. Exosomes Pipeline Therapeutics
6. Exosomes Late Stage Products (Phase II/III)
7. Exosomes Mid Stage Products (Phase II)
8. Exosomes Early Stage Products (Phase I)
9. Exosomes Preclinical Stage Products
10. Exosomes Therapeutics Assessment
11. Exosomes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Exosomes Key Companies
14. Exosomes Key Products
15. Exosomes Unmet Needs
16 . Exosomes Market Drivers and Barriers
17. Exosomes Future Perspectives and Conclusion
18. Exosomes Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports:
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regene here
News-ID: 3952472 • Views: …
More Releases from DelveInsight Business Research
Von Willebrand Disease Market Insights Highlight Expanding Outlook Till 2034, De …
DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease…
Global Artificial Kidney Market to reach USD 6.09 billion by 2032 at a CAGR of 1 …
According to DelveInsight's analysis, The growing demand for artificial kidneys is primarily fueled by the increasing prevalence of kidney failure and end-stage renal disease (ESRD), alongside a rising incidence of contributing factors such as diabetes, hypertension, and an aging global population. These trends are driving the need for advanced and efficient renal care technologies. Moreover, the expanding preference for home-based dialysis solutions, combined with continuous technological innovations and frequent product…
Global Bladder Scanners Market to grow at a CAGR of 6.12% by 2032, Evaluates Del …
According to DelveInsight's analysis, The growing prevalence of urinary disorders such as incontinence, urinary retention, and overactive bladder especially among the aging population continues to drive demand for bladder scanners. The increasing preference for non-invasive and efficient diagnostic tools is further propelling market growth, as bladder scanners provide a safe, quick, and accurate alternative to traditional catheterization. Their expanding use across hospitals, clinics, and home care settings highlights their clinical…
Global Transdermal Drug Delivery Devices Market to reach USD 121,798.76 million …
According to DelveInsight's analysis, The rising incidence of chronic diseases, along with the growing adoption of advanced third-generation transdermal drug delivery systems, is substantially driving the global market's growth.
DelveInsight's "Transdermal Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Transdermal Drug Delivery Devices…
More Releases for Exosome
Spotlight on Exosome Delivery Technology - Creative Biolabs Showcased at the 202 …
On September 25, 2025, the multi-day 7th Exosome-Based Therapeutic Development Summit concluded successfully.
New York, USA - October 13, 2025 - During the presentations and panel discussions, participants noted the special benefits exosomes bring-including excellent biocompatibility, low immunogenicity, and the ability to cross biological barriers-reiterating their great promise in cancer treatment, neurological disorders, and immune regulation. When compared with liposomes and traditional nanoparticles, exosomes offer greater efficiencies in carrying nucleic acids,…
Emerging Trends to Reshape the Exosome Technologies Market: Creative Biolabs Lau …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Exosome Technologies Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the exosome technologies market size has seen a significant exponential growth. The market is projected to expand from $0.07 billion in 2024 to $0.09 billion in 2025, with a compound…
Exosome Therapy Market May See a Big Move | Major Giants- Exiqon, Exosome Diagno …
HTF MI recently introduced Global Exosome Therapy Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborating market size (2024-2031). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence.
The Major Players Covered in this Report: Sistemic Ltd Aethlon Medical, Inc. (United States), Exosome Diagnostic, Inc. (United States), Thermo Fisher Scientific, Inc. (United…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
Exosome Technologies Market Report 2024 - Exosome Technologies Market Size, Shar …
"The Business Research Company recently released a comprehensive report on the Global Exosome Technologies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The exosome technologies market size…
Exosome technologies Market Growth Expected to See Next Level | Exosome Diagnost …
The Latest Study Published by HTF MI Research on the "Exosome technologies Market'' evaluates market size, trend and forecast to 2030. The Exosome technologies market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges as well…
